Reorienting the Fab domains of trastuzumab results in potent HER2 activators. - Wikidata - wikimedia - TriplyDB

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

http://www.wikidata.org/entity/Q34532338

about

Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities.Structure of the Plexin Ectodomain Bound by Semaphorin-Mimicking Antibodies.Fab-based bispecific antibody formats with robust biophysical properties and biological activity The Mysterious Ways of ErbB2/HER2 Trafficking The role of neratinib in HER2-driven breast cancer.Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.

P2860

Q35168105-D0BBB835-E14E-478D-A5FC-0632709C930E Q36040189-06D5FFFA-BDBB-4281-8F2F-338992BC9709 Q36213193-14B2CF08-429D-4034-A0C7-328BFB1595B5 Q38237727-D66F1540-D747-4F64-819C-A2E79E7E5E8B Q38664492-0C30098A-E2CF-4622-AE6D-A3168FDEA72D Q41838529-A46EDDF8-76D1-48BE-B481-834F3778D711 Q51028189-3D165F28-B45F-4409-B720-98CE4671E88F

P2860

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

http://www.wikidata.org/entity/Q34532338

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@ast

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@en

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@nl

type

label

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@ast

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@en

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@nl

prefLabel

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@ast

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@en

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@nl

P1433

Q34532338-099EB095-4503-43A3-BA2A-70BE3B4F6F80

P1476

Q34532338-9243698B-D783-4707-8F6C-5C885CDE1DC3

P2093

Q34532338-49784048-BE23-472D-8C93-319BDEF4CB82

Q34532338-4B421448-38B3-4CBA-B9D9-6BB30B102639

Q34532338-52A7DD09-4504-48FA-9A45-77C4AD74A2EA

Q34532338-9065E6AE-15A8-4E9B-8872-9BC4F0900345

Q34532338-C40740E5-C9BF-45C1-B641-F98157F93A60

Q34532338-C6BA03D8-D7DE-4394-8D13-F39B7C65D568

Q34532338-CF1383EE-3CE8-44C9-83C1-5305668CE18D

Q34532338-FFA8E719-A870-411B-8CF7-CF406E736E50

P2860

Q34532338-013A6ABF-A853-4F66-B897-FDADC2851620

Q34532338-1245797B-D5AD-44B6-BB61-A3F0AE3CE215

Q34532338-15A0332F-15FF-4796-86C9-C9CB837347F0

Q34532338-18896C69-2454-49DD-BE8F-FE81C5BA898B

Q34532338-1907DF41-FB26-4DE8-84D7-8CDD311BD15E

Q34532338-1B3BC680-01C5-4784-9E3B-6B1C94990595

Q34532338-1B554CB8-35DD-463B-BEAF-6DE87F220D88

Q34532338-2832F2E3-6C1D-4284-9DF8-FE8784EF9597

Q34532338-2C3E3A38-D285-4D0B-A938-779E12B21D8B

Q34532338-2D554D20-9264-4117-A7F7-F2876A6C6435

P304

Q34532338-ABEA7DC0-8C4A-4916-8DD5-1F6486C7F693

P31

Q34532338-F05E7AF8-2A6A-4483-A454-6F2016A90298

P356

Q34532338-A7A42190-9234-4C9E-B1B2-E28B3B5D3D1F

P407

Q34532338-9B2F9E24-398D-42F1-8DE0-DCED383190DD

P433

Q34532338-E2ABF456-3154-4068-B9F7-1DD3F454946D

P478

Q34532338-0A9B8644-AE40-441E-B701-8B5F2F97EC8C

P577

Q34532338-A91FA003-DABD-43D0-87FB-922D52245544

P5875

Q34532338-D54ABABF-AFBD-4D84-BBC7-0B24D327B4FA

P698

Q34532338-58098A11-7D80-431C-B9D1-68EFBBCDC89B

P932

Q34532338-701DFB9A-2C5C-4AD6-AE2F-525FEA2DD65D

P356

JOURNAL.PONE.0051817

P1433

P1476

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

@en

P2093

Elizabeth Luis

http://www.w3.org/2001/XMLSchema#string

Gabriele Schaefer

http://www.w3.org/2001/XMLSchema#string

J Michael Elliott

http://www.w3.org/2001/XMLSchema#string

Justin M Scheer

http://www.w3.org/2001/XMLSchema#string

Lily Shao

http://www.w3.org/2001/XMLSchema#string

Richard Vandlen

http://www.w3.org/2001/XMLSchema#string

Sock-Cheng Lewin-Koh

http://www.w3.org/2001/XMLSchema#string

Wendy Sandoval

http://www.w3.org/2001/XMLSchema#string

P2860

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Untangling the ErbB signalling network

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling.

P304

e51817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0051817

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234043613

http://www.w3.org/2001/XMLSchema#string

P698

23284778

http://www.w3.org/2001/XMLSchema#string

P932

3527469

http://www.w3.org/2001/XMLSchema#string